A phase I trial of docetaxel and pulse-dose 17-allylamino-17- demethoxygeldanamycin in adult patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 1089-1097

  Iyer, Gopa ^a   Morris, Michael J ^a   Rathkopf, Dana ^a   Slovin, Susan F ^a   Steers, Macaulay ^a   Larson, Steven M ^a   Schwartz, Lawrence H ^a   Curley, Tracy ^a   DeLaCruz, Anthony ^a   Ye, Qing ^a   Heller, Glenn ^a   Egorin, Merrill J ^b   Ivy, S Percy ^c   Rosen, Neal ^a   Scher, Howard I ^a   Solit, David B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

17 AAG; Docetaxel; Geldanamycin; Hsp90; Phase I

Indexed keywords

DIMETHYL SULFOXIDE; DOCETAXEL; HEAT SHOCK PROTEIN 90; TANESPIMYCIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLADDER CANCER; BONE PAIN; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PAIN; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOBLOTTING; INSOMNIA; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; THORAX PAIN; THROMBOSIS; URINARY FREQUENCY; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TAXOIDS;

EID: 84859794081     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1789-3     Document Type: Article

References (32)

1. Solit DB, Rosen N (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6:1205-1214 (Pubitemid 44120915)
2. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549
3. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161 (Pubitemid 46211321)
4. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S et al (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087 (Pubitemid 46202262)
5. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R et al (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893 (Pubitemid 46211366)
6. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG et al (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11:3385-3391 (Pubitemid 40627891)
7. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF et al (2007) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775-1782 (Pubitemid 46952945)
8. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250 (Pubitemid 27199896)
9. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273-279 (Pubitemid 28393843)
10. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796-22801 (Pubitemid 26304727)
11. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N (1995) Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 270:16580-16587
12. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D et al (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993 (Pubitemid 34517631)
13. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63:2139-2144 (Pubitemid 36538618)
14. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277:39858-39866 (Pubitemid 35190971)
15. Schulte TW, Blagosklonny MV, Ingui C, Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-24588
16. Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: Sausville EA, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 7:2155-2158, 2228-2236
17. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB et al (2006) Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5:1197-1208 (Pubitemid 43881312)
18. Nguyen DM, Lorang D, Chen GA, Stewart JHt, Tabibi E, Schrump DS (2001) Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 72:371-378; discussion 8-9
19. Nguyen DM, Chen A, Mixon A, Schrump DS (1999) Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. J Thorac Cardiovasc Surg 118:908-915 (Pubitemid 29511075)
20. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291-302 (Pubitemid 32640768)
21. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 783:231-236 (Pubitemid 35351650)
22. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 6:79-98 (Pubitemid 8314204)
23. Rocci ML Jr, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203-216
24. Ficker E, Dennis AT, Wang L, Brown AM (2003) Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92:e87-e100
25. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H et al (2004) Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11:787-797 (Pubitemid 38836895)
26. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410 (Pubitemid 37187270)
27. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y et al (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702-3708
28. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA et al (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29:325-334
29. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C et al (2011) The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 30:2581-2586
30. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R et al (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28:4953-4960
31. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N et al (2011) HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clin Cancer Res 17:5132-5139
32. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L et al (2006) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103:17408-17413 (Pubitemid 44788982)